• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Federal investigators subpoena Biogen over MS drug prices

February 3, 2017 By Sarah Faulkner

Federal investigators subpoena Biogen over MS drug pricesBiogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy.

In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details.

Effective Jan. 1, Biogen hiked the U.S. prices of Tecfidera, Avonex and Plegridy by 8% each and Tysabri by 3.5%.

On Thursday, BIIB shares fell -7% to $263.35 apiece after the company’s hemophilia spin-off, Bioverativ, made its debut on the NASDAQ market.

Bioverativ set out with Biogen’s 2 approved hemophilia drugs, Eloctate and Alprolix, and $325 million in cash. The spin-off is listed under the symbol “BIVVV” and was trading at $44.04 apiece in mid-morning activity today, down -2.1%.

Also this week, Biogen met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected.

The biopharmaceutical company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. 31, for bottom-line loss of -21.9% on sales growth of 1.1% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $5.09, ahead of consensus on The Street, where analysts were looking for sales of $2.94 billion.

Drug pricing in the pharmaceutical industry has sparked national debate this year. President Donald Trump recently said that drug companies are “getting away with murder” in regards to what they charge the government for medications.

Trump met with pharma executives this week to address pricing, production and regulations. The president called on the company execs to increase U.S. production and lower “astronomical” drug prices.

Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) told Reuters that they were encouraged by the President’s focus on innovation and that the meeting also touched upon issues like negotiating stronger trade agreements, tax reform and getting rid of outdated regulations.

“Tax, deregulation – those are things that could really help us expand operations,” Lilly CEO Dave Ricks said.

Filed Under: Featured, Legal News, Neurological, Wall Street Beat Tagged With: Biogen Idec, Bioverativ

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS